Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).

Abstract

INTRODUCTION:

Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed. This clinical trial aims to explore safety and pharmacokinetics-pharmacodynamics of a high-dose pyrazinamide-rifampicin regimen.

METHODS AND ANALYSIS:

Adult patients with pulmonary TB admitted to six hospitals in Sweden and subjected to receive first-line treatment are included. Patients are randomised (1:3) to either 6-month standardised TB treatment or a 4-month regimen based on high-dose pyrazinamide (40 mg/kg) and rifampicin (35 mg/kg) along with standard doses of isoniazid and ethambutol. Plasma samples for measurement of drug exposure determined by liquid chromatography tandem-mass spectrometry are obtained at 0, 1, 2, 4, 6, 8, 12 and 24 hours, at day 1 and 14. Maximal drug concentration (Cmax) and area under the concentration-time curve (AUC0-24h) are estimated by non-compartmental analysis. Conditions for early model-informed precision dosing of high-dose pyrazinamide-rifampicin are pharmacometrically explored. Adverse drug effects are monitored throughout the study and graded according to Common Terminology Criteria for Adverse Events V.5.0. Early bactericidal activity is assessed by time to positivity in BACTEC MGIT 960 of induced sputum collected at day 0, 5, 8, 15 and week 8. Minimum inhibitory concentrations of first-line drugs are determined using broth microdilution. Disease severity is assessed with X-ray grading and a validated clinical scoring tool (TBscore II). Clinical outcome is registered according to WHO definitions (2020) in addition to occurrence of relapse after end of treatment. Primary endpoint is pyrazinamide AUC0-24h and main secondary endpoint is safety.

ETHICS AND DISSEMINATION:

The study is approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Informed written consent is collected before study enrolment. The study results will be submitted to a peer-reviewed journal.

TRIAL REGISTRATION NUMBER:

NCT04694586.

• Authors: David Ekqvist, Anna Bornefall, Daniel Augustinsson, Martina Sönnerbrandt, Michaela Jonsson Nordvall, Mats Fredrikson, Björn Carlsson, Mårten Sandstedt, Ulrika S H Simonsson, Jan-Willem C Alffenaar, Jakob Paues, Katarina Niward
• Journal: BMJ open (BMJ Open) Vol. 12 Issue 3 Pg. e054788 (03 10 2022) ISSN: 2044-6055 [Electronic] England
• PMID: 35273049 (Publication Type: Clinical Trial Protocol, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Chemical References

• Antitubercular Agents
• Pyrazinamide
• Isoniazid
• Rifampin

Topics

• Adult
• Antitubercular Agents (therapeutic use)
• Clinical Trials, Phase II as Topic
• Drug Therapy, Combination
• Humans
• Isoniazid (therapeutic use)
• Pyrazinamide
• Randomized Controlled Trials as Topic
• Recurrence
• Rifampin
• Tuberculosis (chemically induced, drug therapy)